Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
University of Alberta
$65,000.00
Understanding why some breast cancers resist reovirus oncolysis and expanding reovirus as a cancer therapy towards resistant breast cancers
FY 2023-24
Summary
Breast cancer (BC) accounts for a significant portion of new cancer cases and deaths in Canadian women. Reovirus, a virus harmless to humans, has shown promise in reducing BC tumors and stimulating immune responses. However, fewer than 20% of BC patients respond to it. that BC cells lacking the protein JAM-A resist reovirus, while a modified version, s1?Head, can infect these cells. This study aims to understand why s1?Head is effective in JAM-A-deficient BC cells and evaluate its therapeutic potential in BC animal models with low JAM-A levels. Also, we will discover how much JAM-A is required for reovirus treatment to help guide personalized treatment decisions. By tailoring reovirus for cancer cells based on factors like JAM-A, we aim to unleash the full potential of reovirus for BC therapy.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
516999
Name
Shmulevitz Maya
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Understanding why some breast cancers resist reovirus oncolysis and expanding reovirus as a cancer therapy towards resistant breast cancers
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
Breast cancer (BC) accounts for a significant portion of new cancer cases and deaths in Canadian women. Reovirus, a virus harmless to humans, has shown promise in reducing BC tumors and stimulating immune responses. However, fewer than 20% of BC patients respond to it. that BC cells lacking the protein JAM-A resist reovirus, while a modified version, s1?Head, can infect these cells. This study aims to understand why s1?Head is effective in JAM-A-deficient BC cells and evaluate its therapeutic potential in BC animal models with low JAM-A levels. Also, we will discover how much JAM-A is required for reovirus treatment to help guide personalized treatment decisions. By tailoring reovirus for cancer cells based on factors like JAM-A, we aim to unleash the full potential of reovirus for BC therapy.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Shmulevitz, Maya
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~